Buy Rating for Voyager Therapeutics Driven by Promising Alzheimer’s Gene Therapy and Significant Share Price Potential

In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Voyager Therapeutics, with a price target of $11.00.

Samantha Semenkow’s rating is based on Voyager Therapeutics’ recent advancements in their Alzheimer’s disease program, which have shown promising results. The company has introduced a novel APOE-targeted gene therapy utilizing their proprietary TRACER capsid platform, aiming to reduce APOE4 expression and increase APOE2 expression. This approach is significant as it targets a genetic factor associated with Alzheimer’s risk, and preclinical studies have demonstrated positive outcomes in relevant brain regions of mice models.
Additionally, Voyager’s pipeline includes other innovative therapies such as VY7523, VY1706, and an anti-Aβ therapy, all of which are wholly owned by the company. These developments, combined with the potential for significant share price appreciation, contribute to the Buy rating. The expected share price return of 257.1% further underscores the optimistic outlook on Voyager’s stock.

According to TipRanks, Semenkow is an analyst with an average return of -15.1% and a 29.41% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, Argenx Se, and Sana Biotechnology.